CellaVision AB: Interim Report January-June 2014 Continued

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 18, 2014 at 2:30 AM

CellaVision AB: Interim Report January-June 2014

Continued strong sales growth of 50 percent January 1 - June 30, 2014 * Net sales increased by 39 % to SEK 97.4 million (69.9). * Operating profit increased to SEK 18.3 million (-1.0). * Operating margin was 18.8 %. * Profit before tax increased to SEK 18.9 million (-2.0). * Earnings per share increased to SEK 0.63 (-0.08). April 1-June 30 2014 * Net sales increased by 50 % to SEK 54.2 million (36.1). * Operating profit increased to SEK 10.8 million (-0.4). * Operating margin increased to 19.9 %. * Profit before tax increased to SEK 11.4 million (-0.5). * Earnings per share increased to SEK 0.38 (-0.01). * New technology platform acquired to develop product for small/mid-size laboratories. * CellaVision received the Bede Prize for its ability to develop innovation into useful and profitable products. CEO's comments Sales continue to be strong, with growth of 50 percent and an operating margin of 20 percent. Despite the profit being compared with the weak second quarter of 2013 this growth is very positive. Also in this quarter the North American market primarily accounts for the sales growth (+73 %) where we see continued sound development. EMEA also reports good sales growth (+72 %) and is now at a stabilized level. During the quarter CellaVision received another award; the Bede Prize. This confirms that our team has created a new market in health care by driving a paradigm shift from manual to digital microscopy. Of the available market we have now taken just over eleven percent and in our present market segment CellaVision's products lead with an approximate market share of 95 percent. We see growing interest in the market for digital solutions and increasing competition, with more similar products and new solutions, not least in China. As part of strengthening our product portfolio a new technology platform was acquired that we intend to use as a basis for an analyzer for smaller laboratories presently not included in our target market. With the new platform we may increase the potential numbers of customers three times to 45,000 laboratories. The potential world market will increase about 30 percent to 10 billion SEK. However, we estimate that it could take a couple of years before these products are available. Our new products, the CellaVision® DM9600 and the Advanced RBC Application, have had a very positive reception, which strengthens our market position and is a recognition of our ability to develop technological solutions. The products will be shown at the AACC Annual Meeting in Chicago at the end of July and the first analyzers were delivered at the start of the month. Work still remains to be done on registration and market introductions to replace our most sold product, the DM96, with the DM9600. As a result of this sales of the DM9600 are expected to be somewhat slow, which may impact the next quarter. Yvonne Mårtensson, President and CEO Key ratios (MSEK) Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec 2014 2013 2014 2013 2013 ----------------------------------------------------------------- Net sales 54.2 36.1 97.4 69.9 179.9 ----------------------------------------------------------------- Gross profit 36.3 23.4 64.3 45.4 112.6 ----------------------------------------------------------------- Operating profit 10.8 -0.4 18.3 -1.0 25.9 ----------------------------------------------------------------- Operating margin, % 19.9 Neg 18.8 Neg 14.4 ----------------------------------------------------------------- Profit/loss before tax 11.4 -0.5 18.9 -2.0 24.7 ----------------------------------------------------------------- Cash flow for the period -30.0 -11.4 -11.7 -5.1 11.6 ----------------------------------------------------------------- Questions concerning the report can be addressed to: Yvonne Mårtensson, CEO, CellaVision AB Tel: +46 708 33 77 82. Email: yvonne.martensson@cellavision.se Magnus Blixt, CFO, CellaVision AB Tel: +46 708 33 81 68. Email: magnus.blixt@cellavision.se [HUG#1830092]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...